Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05618717 · ClinicalTrials.gov registry record

Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia

A clinical trial, sponsored by Rush University Medical Center.

Completed
Registry status
103
Enrollment target

NCT05618717 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 103 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05618717 has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
103 participants
Enrollment target

Study Summary

Vistag SurPoint is a proprietary module that generates a numerical tag index which can be used as multiparametric lesion quality marker to guide ablation in the clinical setting for ablation of atrial arrhythmias. SurPoint tag index has studied to guide ablation of ventricular arrhythmias, such as premature ventricular complexes, but its effectiveness and safety for ablation of Ventricular Tachycardia in patient with Ischemic and Non-Ischemic Cardiomyopathies is not well established. In this single center prospective observation registry, a ventricular ablation strategy utilizing radiofrequency delivery duration cut off determined by a maximum Surpoint index value of 550 will be compared to conventional operator determined duration of radiofrequency delivery based on combination of time (i.e. 30, 60, 90, and 120 seconds), magnitude of impedance drop, attenuation of abnormal electrograms, and achieving non-capture with high-output pacing after ablation. The Surpoint Tag Index Ablation group will be matched with a control group of patients undergoing VT ablation using the conventional time-based radiofrequency strategy and the patients in this group will be selected using propensity matching based on relevant baseline patient and clinical characteristic variables. Primary outcomes of interest: Recurrence of sustained ventricular tachycardia or Internal Cardiac Defibrillator Therapy. Secondary outcomes of interest: Hospitalization for ventricular tachycardia, repeat ablation procedures, all-cause mortality, acute procedural complications, rate of steam pops during ablation procedures Follow up: Up to 24 months after ablation procedure. Follow up will be obtained by office visits and device interrogation reports.

Interventions

  • DEVICE Radiofrequency Ablation

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2018-01-01
Est. Completion 2023-01-31

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT05618717

The ClinicalTrials.gov registry entry for NCT05618717 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Radiofrequency Ablation is the first listed.

NCT05618717 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05618717 about?

NCT05618717 is a clinical study titled "Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia". Vistag SurPoint is a proprietary module that generates a numerical tag index which can be used as multiparametric lesion quality marker to guide ablation in the clinical setting for ablation of atrial arrhythmias. SurPoint tag index has studied to guide ablation of ventricular arrhythmias, such as p...

What is the current status of trial NCT05618717?

This trial is currently completed. The enrollment target is 103 participants. The study started on 2018-01-01. Estimated completion is 2023-01-31.

What interventions are being tested in trial NCT05618717?

The interventions under investigation include: Radiofrequency Ablation (DEVICE).

Who is sponsoring clinical trial NCT05618717?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.